A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

British Journal of Cancer

Volumn 98, Issue 1, 2008, Pages 80-85

  Eskens, F A L M ^a   Mom, C H ^b   Planting, A S T ^a   Gietema, J A ^b   Amelsberg, A ^c   Huisman, H ^d   Van Doorn, L ^a   Burger, H ^a   Stopfer, P ^d   Verweij, J ^a   De Vries, E G E ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

BIBW 2992; Epidermal growth factor receptor; Pharmacokinetics; Phase I; Tyrosine kinase inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIBW 2992; BILIRUBIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LOPERAMIDE; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ELECTROCARDIOGRAM; EPISTAXIS; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KERATINOCYTE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN BIOPSY; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KERATINOCYTES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SKIN; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 38049038935     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604108     Document Type: Article

References (20)

1. Agus D, Terlizzi E, Stopfer P, Amelsberg A, Gordon M (2006) A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol 24: 49s (suppl, abstract 2074)
2. Baselga J, Rischin D, Ranson M, Cavert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Averbuch S, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302
3. Burris H, Hurwitz H, Dees E, Dowlati A, Blackwell K, O'Neil B, Marcom P, Ellis M, Overmoyer B, Jones S, Harris J, Smith D, Koch K, Stead A, Mangum S, Spector N (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23: 5305-5313
4. Carter E, Wodicka L, Shah N, Velasco A, Fabian M, Treiber D, Milanov Z, Atteridge C, Biggs W, Edeen P, Floyd M, Ford J, Grotzfeld R, Herrgard S, Insko D, Mehta S, Patel H, Pao W, Sawyers C, Varmus H, Zarrinkar P, Lockhart D (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102: 11011-11016
5. Dittrich Ch, Greim G, Borner M, Weigang-Köhler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, Fumoleau P (2002) Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 38: 1072-1080
6. Ehrlichman C, Hidalgo M, Boni J, Martins P, Quinn S, Zacharchuk C, Amorusi P, Adjei A, Rowinsky E (2006) Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 24: 2252-2260
7. Geyer C, Forster J, Lindquist D, Chan S, Romieu S, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin S, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med 355: 2733-2743
8. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond L, Takimoto C, Eckhardt SG, Tolcher A, Britten C, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky E (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279
9. Hoekstra R, Dumez H, Eskens FALM, van der Gaast A, Planting A, de Heus G, Sizer K, Ravera C, Vaidyanathan S, Bucana C, Fidler I, van Oosterom A, Verweij J (2005) Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 11: 6908-6915
10. Hynes N, Lane H (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354
11. Kwak E, Sordella R, Bell D, Godin-Heymann N, Okimoto R, Brannigan B, Harris P, Driscoll D, Fidias P, Lynch T, Rabindran S, McGinnis J, Wissner A, Sharma S, Isselbacher K, Settleman J, Haber D (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665-7670
12. Lewis N, Marshall J, Amelsberg A, Cohen R, Stopfer P, Hwang J, Malik S (2006) A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. J Clin Oncol 24: 49s (suppl, abstract 3091)
13. Munster P, Britten C, Mitta M, Gelmon K, Minton S, Moulder S, Slamon D, Guo F, Letrent S, Denis L, Tolcher A (2007) First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res 15: 1238-1245
14. Playford R, Hanby A, Gschmeissner S, Peiffer L, Wright N, McGarrity T (1996) The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract. Gut 39: 262-266
15. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray P, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky E (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20: 2240-2250
16. Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322
17. Shaw H, Plummer R, Vidal L, Perrett R, Pilkington M, Temple G, Fong P, Amelsberg A, Calvert H, De Bono J (2006) A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours. J Clin Oncol 24: 49s (suppl, abstract 3027)
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan R, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom A, Christian M, Gwyther S (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
19. Torrance C, Jackson P, Montgomery E, Montgomery E, Kinzler K, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani C (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024-1028
20. Toyoshima H, Hunter T (1994) p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78: 67-74